A wearable technology enables real-time, noninvasive tracking and optimized treatment for diabetic patients. It enables precise drug dosing through continuous, real-time monitoring of disease and drug markers. Based on microneedles, the system continuously monitors — via the interstitial fluid in the skin — glucose levels and the level of metformin, a common diabetes medication.
The new technology solves these problems through continuous monitoring of biological markers and medications using an array of microneedles, which adheres to the skin without causing pain and monitors glucose and drug levels in real time. The platform system combines 3D printed microneedles, nano-enzyme-based sensors, smartphone connectivity, and a dedicated app that enables pharmacologically guided diabetes treatment.
It operates as a closed loop: the microneedles penetrate the upper skin layer and monitor biomarkers found in the interstitial fluid. Using unique sensors containing nano-enzymes, the system continuously and accurately measures glucose and metformin levels. The signals are transmitted via Bluetooth to a mobile phone app, which performs real-time pharmacokinetic (PK) and pharmacodynamic (PD) analyses and generates personalized drug profiles and dosage recommendations. The app alerts users or caregivers immediately to any significant changes.
